Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11644MR)

This product GTTS-WQ11644MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11644MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10732MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ7389MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ5432MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ11274MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ8598MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ14991MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ7027MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ3487MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BA1126
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW